KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Accumulated Depreciation (2020 - 2022)

Historic Accumulated Depreciation for AbCellera Biologics (ABCL) over the last 3 years, with Q4 2022 value amounting to $18.5 million.

  • AbCellera Biologics' Accumulated Depreciation rose 8802.16% to $18.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was $18.5 million, marking a year-over-year increase of 8802.16%. This contributed to the annual value of $18.5 million for FY2022, which is 8802.16% up from last year.
  • Per AbCellera Biologics' latest filing, its Accumulated Depreciation stood at $18.5 million for Q4 2022, which was up 8802.16% from $15.7 million recorded in Q3 2022.
  • In the past 5 years, AbCellera Biologics' Accumulated Depreciation registered a high of $18.5 million during Q4 2022, and its lowest value of $5.6 million during Q4 2020.
  • Its 3-year average for Accumulated Depreciation is $10.7 million, with a median of $9.8 million in 2021.
  • Its Accumulated Depreciation has fluctuated over the past 5 years, first soared by 7590.4% in 2021, then surged by 8802.16% in 2022.
  • Over the past 3 years, AbCellera Biologics' Accumulated Depreciation (Quarter) stood at $5.6 million in 2020, then soared by 75.9% to $9.8 million in 2021, then surged by 88.02% to $18.5 million in 2022.
  • Its last three reported values are $18.5 million in Q4 2022, $15.7 million for Q3 2022, and $13.2 million during Q2 2022.